PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
42.40
-0.71 (-1.65%)
At close: 4:01PM EST

42.92 +0.52 (1.23%)
Pre-Market: 6:18AM EST

Stock chart is not supported by your current browser
Previous Close43.11
Open43.47
Bid42.76 x 800
Ask42.92 x 1000
Day's Range42.04 - 43.50
52 Week Range33.20 - 46.47
Volume29,531,122
Avg. Volume23,473,012
Market Cap245.092B
Beta (3Y Monthly)0.75
PE Ratio (TTM)10.71
EPS (TTM)3.96
Earnings DateJan 29, 2019
Forward Dividend & Yield1.44 (3.29%)
Ex-Dividend Date2018-11-08
1y Target Est44.78
Trade prices are not sourced from all markets
  • TheStreet.com39 minutes ago

    Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

    U.S. stock futures traded higher on Wednesday, Dec. 19, as investors prepped for an announcement from the Federal Reserve on interest rates that comes amid increasing concerns of a global economic slowdown. Contracts tied to the Dow Jones Industrial Average jumped 209 points, futures for the S&P 500 rose 22.25 points, and Nasdaq futures gained 59.75 points. The Fed is widely expected to lift the range of its key fed funds rate by 25 basis points to 2.25% to 2.5%, according to CME Group futures prices, but may drop its reference to the need for "further gradual rate increases" in 2019 as it monitors data both at home and aboard.

  • Drugmaker GSK to split after striking Pfizer consumer health deal
    Reuters43 minutes ago

    Drugmaker GSK to split after striking Pfizer consumer health deal

    GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer health division. The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent.

  • The Wall Street Journal1 hour ago

    [$$] Pfizer and Glaxo to Combine Consumer-Health Businesses

    PLC plan to combine their consumer-health units, and eventually spin off the joint venture—creating a global giant selling drugstore staples like Advil and Sensodyne toothpaste. The deal announced Wednesday is an unexpected ending to a yearlong process by Pfizer to shed its consumer business, as it and other pharmaceutical companies focus more on higher-margin prescription-drugs. Glaxo has been pursuing the same focus, though has until now stayed committed to its consumer business, which its chief executive led before her promotion to the top job.

  • Reuters2 hours ago

    Drugmaker GSK to split after striking Pfizer consumer health deal

    GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer health division. The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent.

  • Glaxo-Pfizer Deal Creates Biggest Over-the-Counter Drug Supplier
    Bloomberg2 hours ago

    Glaxo-Pfizer Deal Creates Biggest Over-the-Counter Drug Supplier

    Glaxo will have a 68 percent controlling stake in the new entity, with combined sales of $12.7 billion. The transaction creates the world’s biggest supplier of over-the-counter medicines with brands of painkillers such as Advil and Panadol and marks a shift from Glaxo Chief Executive Officer Emma Walmsley’s previously stated strategy of keeping the steadily performing consumer and vaccine businesses under the same roof as the more volatile pharma operations. The benefits of separating into two companies -- one focused on prescription medicines and the other on consumer health -- outweigh the advantages that come with a more diversified structure, Walmsley told reporters on a conference call.

  • Associated Press2 hours ago

    GSK, Pfizer to merge their healthcare divisions

    Drugmakers GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating a business with combined sales of 9.8 billion pounds ($12.7 billion). British-based Glaxo will own 68 percent of the joint venture, while U.S.-based Pfizer will own the remaining 32 percent stake. The joint venture will bring together Glaxo's brands such as Sensodyne, Voltaren and Panadol with Pfizer's Advil and Centrum.

  • TheStreet.com2 hours ago

    GlaxoSmithKline, Pfizer Form Consumer Healthcare Group with $13 Billion in Sales

    GlaxoSmithKline also said it would split its remaining pharmaceutical business into two separate divisions, one focused on over-the-counter drugs, the other on prescriptions and vaccines, following the joint venture creation with Pfizer. GlaxoSmithKline will also own 68% of the newly-created group and has another £1 billion in divestments planned over the near-term. "The combination of GSK and Pfizer's consumer healthcare businesses we will create substantial further value for shareholders," said GSK CEO Emma Walmsley.

  • The Wall Street Journal2 hours ago

    [$$] European Equities Market Talk Roundup

    aims at addressing the challenge of future margin compression and heightened competition in the pharmaceutical sector, says CMC Markets’ Michael Hewson. 0825 GMT - GlaxoSmithKline’s plans to demerge its health-care business to create a joint venture with Pfizer makes sense, Jefferies says, as it will create substantial cost-savings and crystallizes value.

  • The Wall Street Journal4 hours ago

    [$$] GlaxoSmithKline, Pfizer to Create Consumer Healthcare JV

    The two companies will combine their consumer-health units to create a single business with combined sales of around 9.8 billion pounds ($12.4 billion), with Glaxo holding a majority 68% stake and Pfizer the remaining 32%. The U.K. pharmaceutical major said it expects to close the deal in the second half of 2019, and it intends to separate the joint venture within three years of it closing through a separate listing on the U.K. market. The combination is expected to be accretive to adjusted earnings and free cashflow in the first full year after it closes, and be accretive to earnings in the second year, Glaxo said.

  • Business Wire4 hours ago

    Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company

    Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.

  • Boeing Is Still among Dow’s Best Performers despite the Sell-Off
    Market Realist13 hours ago

    Boeing Is Still among Dow’s Best Performers despite the Sell-Off

    Over the past month, shares of the Boeing Company (BA) have been battered significantly as a result of multiple headwinds. Boeing holds the eighth-place spot among the 16 Dow 30 stocks that have posted YTD gains. Boeing was the Dow’s top performer for most of 2017, earning its investors 88% in the year.

  • Pfizer: Recent Developments and Analysts’ Recommendations
    Market Realist19 hours ago

    Pfizer: Recent Developments and Analysts’ Recommendations

    On December 14, Pfizer (PFE) announced a dividend of $0.36 for the first quarter of fiscal 2019. Pfizer announced that the dividend would be payable to shareholders on record at the close of the market on February 1. Pfizer’s dividend of $0.36 is 6% higher than the previous dividend of $0.34.

  • Business Wire20 hours ago

    Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.

  • Benzinga21 hours ago

    Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

    Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...

  • 3 Reasons Why Pfizer's Latest Dividend Hike Is Better Than You Might Think
    Motley Foolyesterday

    3 Reasons Why Pfizer's Latest Dividend Hike Is Better Than You Might Think

    Pfizer's 6% dividend increase is good news. But here's what makes it even better.

  • Pfizer (PFE) Stock Moves -1.58%: What You Should Know
    Zacks2 days ago

    Pfizer (PFE) Stock Moves -1.58%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $43.11, marking a -1.58% move from the previous day.

  • Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod
    Zacks2 days ago

    Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod

    Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).

  • Zacks2 days ago

    Lilly (LLY) to Acquire Pain Candidate From Private Biotech

    Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.

  • PR Newswire2 days ago

    Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

    Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments Research collaboration focused on ...

  • Stock Market Power Rankings: Down Is the New Up
    Motley Fool3 days ago

    Stock Market Power Rankings: Down Is the New Up

    They're big, beautiful, and ranked from 1 to 50.

  • Do Analysts See Any Upside for Ionis Stock?
    Market Realist5 days ago

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”

  • Understanding Ionis Pharmaceuticals’ Operational Performance
    Market Realist5 days ago

    Understanding Ionis Pharmaceuticals’ Operational Performance

    In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.

  • Taking Stock of Ionis’s Performance
    Market Realist5 days ago

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.